Tag: Viking Therapeutics
-
Weakness in Viking Therapeutics is an Opportunity
Weakness in Viking Therapeutics (VKTX) is an opportunity. For one, its VK2735 obesity treatment is that trial results show it’s outperforming other products already on the market. As noted by Seeking Alpha, “Semaglutide (Wegovy) only showed an 8% loss after 20 weeks, while tirzepatide (Zepbound) took significantly longer to reach a larger weight loss. According…
-
Viking Therapeutics Could See Substantial Upside this Year
Keep an eye on rebounding shares of Viking Therapeutics (VKTX). Earlier this year, the company reported that the injectable form of its obesity treatment helped patients lose up to 13.1% of their weight after 13 weeks. Then, the company said the tablet form of its treatment led to a weight loss of about 3.3% after…
-
Viking Therapeutics Could Rally Above $100 this Year
Keep an eye on rebounding shares of Viking Therapeutics (VKTX). Earlier this year, the company reported that the injectable form of its obesity treatment helped patients lose up to 13.1% of their weight after 13 weeks. Then, the company said the tablet form of its treatment led to a weight loss of about 3.3% after…